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ABSTRACT
Virus-specific CD8 T cells are rarely detectable ex vivo by conventional methods during chronic hepatitis C virus (HCV) infec-
tion. In this study, however, we were able to detect and characterize HCV-specific CD8 T cells in all chronically HCV genotype
1a-infected, HLA-A*02:01-positive patients analyzed by performing major histocompatibility complex (MHC) class I tetramer
enrichment. Two-thirds of these enriched HCV-specific CD8 T-cell populations displayed an effector memory phenotype,
whereas, surprisingly, one-third displayed a naive-like phenotype despite ongoing viral replication. CD8 T cells with an effector
memory phenotype could not expand in vitro, suggesting exhaustion of these cells. Interestingly, some of the naive-like CD8 T
cells proliferated vigorously upon in vitro priming, whereas others did not. These differences were linked to the corresponding
viral sequences in the respective patients. Indeed, naive-like CD8 T cells from patients with the consensus sequence in the cor-
responding T-cell epitope did not expand in vitro. In contrast, in patients displaying sequence variations, we were able to induce
HCV-specific CD8 T-cell proliferation, which may indicate infection with a variant virus. Collectively, these data reveal the
presence of phenotypically and functionally diverse HCV-specific CD8 T cells at very low frequencies that are detectable in all
chronically infected patients despite viral persistence.
IMPORTANCE
In this study, we analyzed CD8 T-cell responses specific for HLA-A*02:01-restricted epitopes in chronically HCV-infected pa-
tients, usingMHC class I tetramer enrichment. Importantly, we could detect HCV-specific CD8 T-cell populations in all pa-
tients. To further characterize these HCV-specific CD8 T-cell populations that are not detectable using conventional tech-
niques, we performed phenotypic, functional, and viral sequence analyses. These data revealed different mechanisms for CD8
T-cell failure in HCV infection, including T-cell exhaustion, viral escape, and functional impairment of naive-like HCV-specific
CD8 T cells.
Low numbers of naive virus-specific CD8 T cells circulate inthe blood of healthy individuals (1, 2). After encountering cog-
nate antigen, for example, during acute hepatitis C virus (HCV)
infection, these virus-specific CD8 T cells are primed to expand
clonally and gain effector functions. In the majority of HCV-in-
fected patients, however, viral evasion strategies impede the im-
mune response and persistent infection ensues. The exact mech-
anisms that contribute to HCV-specific CD8 T-cell failure are
not completely understood, but growing evidence suggests that
T-cell exhaustion and viral escape are primary contributors (3).
Distinct phenotypic characteristics within the HCV-specific
CD8 T-cell compartment accompany both of these processes. In
particular, exhausted CD127 CD8 T cells with an effector
memory phenotype coexpress high levels of inhibitory receptors,
such as programmed cell death-1 (PD-1) and target consensus
epitopes, whereas CD127CD8T cells tend to express low levels
of inhibitory receptors and target variant epitopes (4–7). It is im-
portant to note, however, that HCV-specific CD8 T-cell popu-
lations cannot be detected directly ex vivo in themajority of chron-
ically infected patients (2, 8). Consequently, such phenotypic
studies have been limited by technological constraints to small
numbers of patients. Recently, an ex vivo enrichment protocol
based on the use of major histocompatibility complex (MHC)
class I tetramers that allows the detection and characterization of
rare antigen-specific CD8 T-cell populations as well as an esti-
mation of their frequency has been reported (1, 2). Using this
approach, we previously quantified functionally competent naive
HCV-specific CD8 T cells in healthy donors (2). Here, we used a
similar experimental design to analyzeHCV-specific CD8T cells
that could not be detected by conventional tetramer staining dur-
ing chronic HCV genotype 1a infection. In this study, we found
HCV-specific CD8 T cells in all patients tested as well as a high
proportion of naive-like HCV-specific CD8 T cells in some pa-
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tients. However, the proliferative capability of these cells was in-
tact only in patients who displayed sequence variations in the cor-
responding viral epitopes. In contrast, the presence of consensus
viral sequences was associated with an impaired proliferative ca-
pability, suggesting that in these patients a functional impairment
of naive-like HCV-specific CD8 T cells may contribute to HCV-
specific CD8 T-cell failure.
MATERIALS AND METHODS
Subjects. Seventeen HLA-A*02:01-positive (HLA-A*02:01) subjects
with chronic HCV genotype 1a infection (Table 1) attending the Univer-
sity Hospital of Freiburg were included in the study. In addition, 12 HLA-
A*02:01 healthy individuals were included. Written informed consent
was obtained in all cases, and the study was conducted in accordance with
federal guidelines, local ethics committee regulations, and theDeclaration
of Helsinki (1975). Approval was obtained from the ethics committee of
the Albert-Ludwigs-Universität, Freiburg, Germany. Peripheral blood
mononuclear cells (PBMCs) were isolated from EDTA-anticoagulated
blood by density gradient centrifugation. HLA-A*02:01 expression was
confirmed by 4-digit HLA typing.
Tetramer enrichment. Tetramer enrichment procedures were per-
formed as described previously (2). Briefly, PBMCs were labeled with
tetramers coupled to allophycocyanin (APC), and tetramer-bound cells
were enriched using anti-APC magnetic beads and magnetic columns
(both from Miltenyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer’s instructions. Preenriched, enriched, and depleted
fractions were used for flow cytometric analysis. Between 10 and 1,366
tetramer-positive (tetramer) CD8 T cells were detectable after enrich-
ment. The frequency of each epitope-specific T-cell populationwas deter-
mined using the calculation described by Alanio et al. (1).
Antibodies and multiparametric flow cytometry. The following
monoclonal antibodies (MAbs) were used for phenotypic analysis: (i)
anti-CD27-APC-eFluor780, anti-CD45RA-phycoerythrin (PE), and anti-
CD127-eFluor450 (eBioscience, San Diego, CA); (ii) anti-CD3-Pacific
Blue, anti-CD8-AmCyan, anti-CD8-V500, anti-CD11a-fluorescein iso-
thiocyanate (FITC), anti-CD95-PE, anti-Ki67-FITC, and anti-CCR7-PE-
Cy7 (BDBiosciences,Heidelberg,Germany); (iii) anti-CCR7-FITC (R&D
Systems); and (iv) anti-PD-1-PE-Cy7 (BioLegend, San Diego, CA).
7-AminoactinomycinD (7-AAD; Viaprobe; BDBiosciences) was used for
the exclusion of dead cells. All samples were acquired using a FACSCanto
II flow cytometer (BD Biosciences) and analyzed with FlowJo software
(TreeStar Inc., Ashland, OR).
Peptides and tetramers. Peptides corresponding to HLA-A*02-re-
stricted HCV-derived epitopes (NS31073, CINGVCWTV; NS31406, KLVA
LGINAV; variant, KLVALGVNAV), as well as a cytomegalovirus (CMV)-
derived epitope (NLVPMVATV) and an influenza virus (Flu)-derived
epitope (GILGFVFTL), were synthesized with free amino and carboxy
termini by standard 9-fluorenylmethoxy carbonyl chemistry (Genaxxon
Bioscience, Ulm, Germany). All peptides were dissolved in dimethyl sul-
foxide and diluted in full medium (RPMI with 10% fetal bovine serum,
1%penicillin-streptomycin, and 1.5% 1MHEPES; all from Life Technol-
ogies, Carlsbad, CA) according to previously reported protocols (9). Te-
trameric peptide-MHC class I complexes were generated as described
previously (10).
Intracellular cytokine staining. Intracellular cytokine staining proce-
dures were performed as described previously (11). Briefly, cells were
stimulated with peptide for 1 h in the presence of anti-CD107a-PE (BD
Biosciences) and recombinant human interleukin-2 (rhIL-2; Hoff-
mann-La Roche, Basel, Switzerland), prior to addition of brefeldin A
(GolgiPlug; BD Biosciences), and incubated for an additional 5 h before
staining. Intracellular cytokine production was analyzed by using the fol-
lowing additional MAbs: (i) anti-CD8-APC-H7 and anti-tumor necrosis
factor (anti-TNF)-PE-Cy7 (BD Biosciences) and (ii) anti-gamma inter-
feron (anti-IFN-)-eFluor450 (eBioscience).
MD-DCs and stimulation of CD8T cells.Monocytes were purified,
cultured, and matured to monocyte-derived dendritic cells (MD-DCs) as
described previously (2). Briefly, CD14 cells were selected using mag-
netic beads (Miltenyi Biotec) and cultured for 7 days in the presence of 2
ng/ml rhIL-4 and 10 ng/ml recombinant human granulocyte-macro-
phage colony-stimulating factor (both from Peprotech, Rocky Hill, NJ).
MD-DCs were matured by addition of 10 ng/ml recombinant human
TNF (eBioscience) on day 6.MaturedMD-DCswere pulsedwith a 10M
concentration of the relevant peptide. In parallel, autologous CD8 T
cells were purified using magnetic beads (Miltenyi Biotec) and labeled
with Pacific Blue succinimidyl ester (PBSE; Life Technologies) as de-
scribed previously (2). Subsequently, MD-DCs and CD8 T cells were
cocultured in the presence of anti-CD28 MAb (0.5 g/ml; BD Biosci-
ences) at a ratio of 1:30 (MD-DCs/CD8 T cells). rhIL-2 (20 U/ml) was
added on days 4 and 8. On day 12, cells were used for phenotypic and
functional analyses.
DNA amplification and sequencing.RNAwas extracted from patient
sera using a QIAamp viral RNA minikit (Qiagen, Hilden, Germany) and
then subjected to reverse transcription (RT) and amplification with a
One-StepRT-PCRkit (Qiagen), followed by nested PCRusing aTitanium
Taq PCR kit (Clontech,Mountain View, CA). The following primer com-
binations were used for DNA amplification and sequencing: (i) primers
for RT and the first PCR, 5=-CRTCTGCTCCTGCTTGTGG (genomic lo-
cation 2549; R  A/G) and 5=-ATCCGTGGARTGGCACTCR (genomic
location 4294, R  A/G) for NS31073 and 5=-GACAAAAACCARGYGG
AGGG (genomic location 3516, R A/G and Y C/T) and 5=-GAGGA
CCTTCCCCAGYCC (genomic location 5735, Y C/T) for NS31406 and
(ii) primers for nested PCR, 5=-ATGTGGCCTCTCCTCCTGC (genomic
location 2740) and 5=-GCCACCTGGAAGCTCTGGG (genomic location
4004) for NS31073 and 5=-ATAGCAGGGGYAGCCTGC (genomic loca-
tion 3803, Y  C/T) and 5=-AGCACAGCCYGCGTCATAGC (genomic
location 4905, YC/T) for NS31406. AmplifiedDNAwas purified using a
QuickStep 2 PCR purification kit (EdgeBio, Gaithersburg, MD) and se-
quenced by GATC Biotech (Constance, Germany). The obtained bulk
sequences were analyzed using the Sequencher (version 4.9) program
(Gene Codes, Ann Arbor, MI).
Statistics. Statistical analysis was performed using GraphPad Prism
(version 5) software (GraphPad Prism Software, Inc., La Jolla, CA). All
tests were performed two-tailed and to a significance level of 95%. The
statistical tests used are indicated in the figure legends (*, P 0.05; **, P
0.01; ***, P 0.001; ****, P 0.0001).
RESULTS
Enrichment of HCV-specific CD8 T cells derived from chron-
ically infectedpatients andhealthydonors.First,we analyzed the
ex vivo frequencies of tetramer CD8 T cells specific for two
well-described HLA-A*02-restricted HCV-derived epitopes
(NS31073 and NS31406). We analyzed 17 patients with chronic
HCV genotype 1a infection (Table 1) and could detect HCV-spe-
cific CD8 T cells in 9 of 32 cases (two epitopes were tested in 15
patients; one epitope was tested in 2 patients each). Next, we per-
formed peptide-MHC class I tetramer enrichment for both
epitopes using PBMCs obtained from the same patients. Repre-
sentative plots are shown in Fig. 1A to D. Importantly, for all 32
CD8 T-cell responses that were analyzed, virus-specific CD8 T
cells were detectable (Fig. 1E). For the purposes of this report,
CD8T-cell populations that had an ex vivo frequency of0.01%
tetramer cells among CD8 T cells were classified as “directly
detectable,” whereas those that were detectable only after enrich-
ment were termed “enriched detectable.” Thus, 9 CD8 T-cell
responses were directly detectable, whereas 23 were enriched de-
tectable. Of note, several patients had a directly detectable re-
sponse to one epitope but not to the other. As controls, we also
enriched CD8 T cells specific for HCV, Flu, and CMV from
Nitschke et al.
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healthy donors. We observed clear differences in the frequency of
virus-specific CD8 T cells. The highest frequencies were ob-
served for Flu- and CMV-specific CD8 T cells in healthy donors.
These were in a range similar to that described previously (1).
Chronically HCV-infected patients with directly detectable HCV-
specific CD8 T-cell responses showed the second-highest fre-
quencies of virus-specific CD8 T cells. This is not surprising,
given that these cells were all directly detectable ex vivo and
showed average frequencies of approximately 104 tetramer
CD8T cells after enrichment. This also correlates with the cutoff
of the ex vivo tetramer analysis of 0.01%. Of note, two directly
detectable HCV-specific CD8 T-cell populations had lower fre-
quencies, probably indicating that T-cell frequencies may be un-
derestimated to some degree by the enrichment strategy (Fig. 1C
and D). In contrast, enriched detectable HCV-specific CD8 T
cells showed a significantly lower frequency. Indeed, a frequency
of 104 tetramerCD8 T cells was observed in only a single case
in this group. Healthy donors displayed the lowest frequencies of
HCV-specific CD8 T cells. The frequencies of NS31073-specific
and NS31406-specific CD8
 T cells were similar in all groups (Fig.
1E). Of note, the high tetramer background in the CD8 popu-
lation (Fig. 1A to D) consisted mostly of CD19 B cells, which
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FIG 1 Tetramer enrichment and enumeration of HLA-A*02:01-restricted HCV-specific CD8 T cells. (A to D) Representative flow cytometry plots showing
tetramer stainings of PBMCs from patients with chronic HCV genotype 1a infection before and after magnetic bead enrichment. Numbers represent the
frequency of tetramer (tet) CD8T cells in total CD8T cells. (A) NS31406-specific CD8
T cells of patient 2 were detectable before tetramer enrichment. (B)
NS31073-specific CD8
 T cells of patient 1 were not detectable before tetramer enrichment. Patients 7 (C) and 15 (D) had ex vivo HCV-specific CD8 T-cell
responses near the limit of detection by conventionalmethods forNS31073 (C) andNS31406 (D), respectively. (E) Frequencies of CD8
T cells specific forNS31073
andNS31406 aftermagnetic bead enrichment. TheCD8
T-cell responses of patients with chronicHCV infectionwere considered directly detectable if the ex vivo
tetramer frequency was0.01%. The frequencies of HCV-specific CD8 T cells and Flu/CMV-specific CD8 T cells in PBMCs from healthy donors are shown
for comparison. The percentage of tetramerCD8 T cells as a function of the total number of CD8 T cells is indicated. Each symbol represents a CD8 T-cell
response to one epitope (filled circles, NS31073; empty circles, NS31406; filled squares, CMV/Flu). Horizontal bars representmean values. P values were calculated
using the Mann-Whitney U-test.
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have been described in the literature to bind to MHC class I
tetramers (12). However, the CD8 tetramer population was
free of CD14monocytes, CD19 B cells, CD16 or CD56 NK
cells, and CD4 T cells (data not shown). In conclusion, HCV-
specificCD8T cells are present at very low frequencies in PBMCs
during chronic HCV infection even in the absence of directly de-
tectable ex vivo tetramer staining.
Phenotypic characterization of enriched HCV-specific
CD8 T cells.Next, we performed a detailed phenotypic analysis
of the enriched virus-specific CD8 T cells by using multipara-
metric flow cytometry to determine the coordinate expression of
various surface markers. Naive CD8 T cells are characterized by
the coexpression of CD45RA, CCR7, and CD27 (13). As shown in
Fig. 2A, Flu and CMV-specific CD8 T cells rarely displayed a
naive-like phenotype, indicating that these cells had been primed
in vivo and represent memory populations. As expected and de-
scribed previously, the majority of HCV-specific CD8 T cells
obtained from healthy donors displayed a naive-like phenotype
(2). However, nonnaive HCV-specific CD8 T cells were ob-
served in some seronegative individuals; this finding is consistent
with that of previous studies and likely related to specific T-cell
receptor cross recognition of alternative priming antigens (14–
17). Furthermore, most directly detectable HCV-specific CD8
T-cell responses showed a predominantly antigen-experienced
phenotype. Only four directly detectable HCV-specific CD8 T-
cell responses showed relatively high frequencies of cells with
naive-like phenotypes (23.93% to 42.08%; Fig. 2A and B). This
may be linked, for example, to incomplete priming of the original
naive CD8 T-cell population. Enriched detectable HCV-specific
CD8 T cells, however, showed a more heterogeneous differenti-
FIG 2 Phenotypic characterization of enriched HLA-A*02:01-restricted HCV-specific CD8 T cells. (A) Frequency of tetramerCD8 T cells with a naive-like
phenotype (CD45RA CCR7 CD27) within the total enriched tetramer CD8 T-cell population. Epitopes NS31073 and NS31406 from HCV in chronically
HCV-infected patients were analyzed and compared to NS31073 and NS31406 as well as epitopes from CMV and Flu in healthy donors. Patients were grouped as
described in the legend to Fig. 1E. Each symbol represents a CD8 T-cell response to one epitope (filled circles, NS31073; empty circles, NS31406; filled squares,
CMV/Flu). P values were calculated using one-way analysis of variance. Horizontal bars represent mean values. (B to D) Representative flow cytometry
histograms showing the expression of CD45RA, CCR7, CD27, CD127, and PD-1 on enriched tetramerCD8 T cells (black) and bulk CD8 T cells (solid gray)
in PBMCs from patients with chronic HCV infection. (B) Phenotypic characterization of directly detectable HCV-specific CD8 T-cell responses with a high
frequency of naive-like CD8 T cells. NS31073-specific CD8
 T-cell populations from patients 7 (top) and 10 (bottom) are displayed. (C) Enriched detectable
HCV-specificCD8T-cell populationswith a predominantly naive-like tetramerCD8T-cell phenotype are shown, from top to bottom, forNS31073 in patient
14 andNS31406 in patients 6 and 7, respectively. (D) Enriched detectableHCV-specific CD8
T-cell populations with a predominant effectormemory phenotype
are shown, from top to bottom, forNS31073 in patients 1, 5, and 6, respectively. (E) Bar diagram showing the coordinate expression of CD45RA, CCR7, andCD27
on tetramer CD8 T cells from patients with enriched detectable HCV-specific CD8 T-cell responses. The expression profile of the phenotypic markers is
indicated below the diagram (13). Black bars, HCV-specific CD8 T-cell populations with a predominantly (60%) naive-like HCV-specific CD8 T-cell
population (n 9); white bars, HCV-specific CD8 T-cell populations with60% naive-like CD8 T cells (n 15). Bars indicate mean values, and error bars
indicate standard deviations. P values were calculated using two-way analysis of variance followed by Bonferroni’s posttest. max, maximum.
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ation profile (Fig. 2A), ranging from a predominantly naive-like
CD45RA CCR7 CD27 phenotype with high levels of CD127
expression (Fig. 2C and E) to an effector memory CD45RA
CCR7 CD27 phenotype with high expression levels of the ex-
haustion marker PD-1 (Fig. 2D and E). Low CD11a expression
and a lack of the proliferationmarker Ki67 further indicate a naive
phenotype of these cells (Fig. 3A and B). In addition, we analyzed
CD95 expression, which has been suggested to distinguish truly
naive CD95 T cells and CD95 stem cell memory T (TSCM) cells
(18, 19). The absence of CD95 expression points toward a naive
status of HCV-specific CD8 T cells with a CD45RA CCR7
CD27 phenotype (Fig. 3C). In sum, small numbers of HCV-
specific CD8 T cells with an effector memory or naive-like phe-
notype are present at levels below the limit of detection by con-
ventional tetramer staining in patients with chronic HCV
infection. Notably, both effector memory and naive-like CD8 T
cells specific for the NS31073 and NS31406 epitopes could be found
in individual patients (Table 1). This observation suggests that
neither low viral titers nor specific host genetic features in isola-
tion can explain the presence of naive-like HCV-specific CD8 T
cells during chronic HCV infection.
Functional capacities of naive-like CD8 T-cell populations
derived from patients with chronic HCV infection. Subse-
quently, we analyzed the proliferative capacity of enriched detect-
able HCV-specific CD8 T-cell populations. Naive CD8 T cells
classically retain the ability to proliferate vigorously in response to
appropriate priming. To address whether naive-likeHCV-specific
CD8T cells can be primed and proliferate in the chronic phase of
infection, we stimulated patient-derived CD8 T cells with pep-
tide-pulsed autologous monocyte-derived dendritic cells (MD-
DCs) for 12 days and performed a combined phenotypic and
functional analysis. As shown for one representative patient (Fig.
4A), two of five HCV-specific CD8 T-cell populations with a
predominantly (60%)naive-like phenotypewere able to expand
upon specific stimulation (Fig. 4B). Functional analyses revealed
that the expanded CD8 T-cell populations were able to produce
both IFN- and TNF as well as to weakly mobilize CD107a (Fig.
4C). To confirm that naive-like epitope-specificCD8Tcells con-
tributed directly to the expanded response in vitro, we sorted na-
ive-like CD8 T cells (CD45RA CD27) from patient-derived
PBMCs prior to stimulationwith peptide-pulsed autologousMD-
DCs. As shown in Fig. 4D, these sorted cells were able to prolifer-
ate, suggesting that in some patients with chronic HCV infection,
naive-like HCV-specific CD8 T cells can expand in vitro. In con-
trast, HCV-specific CD8 T-cell populations with an effector
memory phenotype were unable to proliferate upon specific stim-
ulation (Fig. 4B). This lack of proliferation in combination with
the observed high expression of PD-1 (Fig. 2D) may indicate that
these cells are in a state of exhaustion (20, 21). Even though we
detected small amounts of naive-like HCV-specific CD8 T cells
in predominantly effector memory phenotype populations (Fig.
2A), these were unable to proliferate in vitro.
Viral sequence analysis of corresponding epitopes. The anti-
gen recognition and, thus, the phenotype of HCV-specific CD8
T cells can be affected by the presence of sequence variations in
viral epitopes, as previously described (4). Thus, we analyzed bulk
viral sequences corresponding to the epitopes NS31073 and
NS31406 from patients with enriched detectable HCV-specific
CD8 T-cell responses (Table 1). In our cohort, all patients
showed the genotype 1a consensus sequence for the NS31073
epitope, whereas most patients showed viral sequence variations
for the NS31406 epitope. This was independent of the naive-like or
effector memory phenotype of HCV-specific CD8 T cells. Since
we were able to expand only two out of five HCV-specific CD8
T-cell populationswith a predominantly naive-like phenotype, we
next investigated whether there is a correlation between sequence
variations in the corresponding viral epitope and the proliferative
capacity of naive-like HCV-specific CD8 T cells, as observed in
Fig. 4B. In HCV-specific CD8 T-cell epitopes with the genotype
1a consensus sequence, we did not observe HCV-specific CD8
T-cell proliferation. In contrast, in the two patients where we
found in vitro expansion of naive-like HCV-specific CD8T cells,
viral sequence variations in the corresponding CD8 T-cell
epitopes were detectable (Table 2). These results suggest that the
sequence variations may not have developed during chronic in-
fection (viral escape) but may have already been present in the
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FIG 3 Phenotypic characterization of naive-like enrichedHLA-A*02:01-restrictedHCV-specific CD8T cells. Representative flow cytometry plots showing the
expression of CD11a (A), Ki67 (B), and CD95 (C) on naive-like (CD45RA CCR7 CD27 CD127) CD8 T cells in PBMCs from patients 14 (NS31406) (A),
3 (NS31073) (B), and 8 (NS31406) (C) with chronic HCV infection. Naive-like tetramer
 CD8 T cells (black) are shown overlaid on bulk CD8 T cells (gray).
Numbers represent the frequency of expression on naive-like tetramer CD8 T cells.
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infecting virus. To confirm this point, we analyzed the effect of the
viral sequence variations on HCV-specific CD8 T-cell prim-
ing. Patient 6 showed a high frequency of naive-like NS31406-
specific CD8 T cells and sequence variation in the NS31406
epitope. We pulsed MD-DCs from this patient with the con-
sensus as well as the autologous variant sequence of NS31406
and used these sequences to stimulate the naive-like HCV-
specific CD8 T cells. Importantly, proliferation of naive-like
NS31406-specific CD8
 T cells could only be observed using the
consensus sequence and not the autologous variant sequence,
indicating a lack of recognition of the variant sequence (Fig. 5).
This finding suggests that functional, naive-like HCV-specific
CD8 T cells directed against the consensus epitope may per-
sist only in patients infected with viral variants.
FIG 4 Proliferation of patient-derived enriched detectable HCV-specific CD8 T cells after stimulation with autologous peptide-pulsed MD-DCs. (A) Repre-
sentative flow cytometry plot showing the proliferation of NS31406-specific CD8
 T cells with a predominantly naive-like phenotype from patient 7 with chronic
HCV infection. CD8 T cells were labeled with PBSE and then stimulated for 12 days with NS31406 peptide-pulsed autologous MD-DCs. Proliferation was
measured by PBSE dilution. The frequency of PBSElow tetramerCD8 T cells in total CD8 T cells is indicated. (B) Frequency of tetramerCD8 T cells after
12 days of stimulation with NS31073 or NS31406 peptide-pulsed autologous MD-DCs. Only patients with enriched detectable epitope-specific CD8
 T-cell
populations were analyzed. HCV-specific CD8 T-cell responses with60% naive-like CD8 T cells were grouped as naive-like. Each dot represents a CD8
T-cell response to one epitope. P values were calculated using the Mann-Whitney U test. Horizontal bars represent mean values. (C) Representative flow
cytometry plots showing the production of IFN- and TNF as well as CD107a mobilization of the in vitro-expanded HCV-specific CD8 T cells from patient 7.
Results for unstimulated (top) andNS31406 peptide-stimulated (bottom) samples are shown.Numbers indicate the percentage ofmarker-positive PBSE
lowCD8
T cells after subtraction of the background. (D) CD8 T cells were enriched from patient-derived PBMCs by using magnetic beads and further sorted by flow
cytometry on the basis of CD45RA and CD27 coexpression (left). The purified CD8 CD45RA CD27 cells were labeled with PBSE and stimulated with
NS31406 peptide-pulsed autologous MD-DCs for 12 days (right). Patient 6 was selected for the experiment whose results are shown on the basis of the presence
of NS31406-specific CD8
 T cells with a predominantly naive-like phenotype during chronic HCV infection.
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DISCUSSION
In this study, we set out to detect and characterize HCV-specific
CD8 T cells derived from chronically HCV genotype 1a-infected
patients without HCV-specific CD8 T-cell responses detectable
by conventional tetramer staining. Therefore, we used an MHC
class I tetramer enrichment protocol that allows the detection of
epitope-specific CD8 T-cell populations present at very low
numbers (1). We decided to analyze two well-described HLA-
A*02:01-restricted CD8 T-cell epitopes, NS31073 and NS31406,
which are frequently recognized (8, 22). Our results show that by
using the tetramer enrichment strategy, HCV-specific CD8 T-
cell populations are detectable in all patients with chronic HCV
infection, even in those without detectable responses ex vivo. Im-
portantly, in chronically infected patients with enriched detect-
able HCV-specific CD8 T-cell responses, we observed heteroge-
neous T-cell phenotypes. Nine of 23 enriched detectable HCV-
specific CD8 T-cell responses displayed a naive-like phenotype
(Fig. 2A). The low frequencies of naive-likeHCV-specific CD8T
cells in HCV-infected patients are in line with the low numbers of
these cells in healthy donors (2). The other 14HCV-specificCD8
T-cell responses displayed an effector memory phenotype with a
high expression of the inhibitory receptor PD-1, a marker of
CD8 T-cell exhaustion (4). It has been described that exhausted
HCV-specific CD8 T cells can be deleted from the T-cell pool
(21). This in turn may also explain the low numbers of epitope-
specific CD8 T cells in many chronically infected patients. Thus,
both the naive-like and the exhausted effectormemory phenotype
may explain the absence of ex vivo-detectableHCV-specific CD8
T-cell counts in these chronically HCV-infected patients.
To the best of our knowledge, the presence of naive-like virus-
specific CD8 T cells despite ongoing viral replication has not
been described previously in humans. The presence of naive-like
HCV-specific CD8 T-cell populations after enrichment may be
explained by an impaired priming of these CD8 T cells during
acute infection, a process that we sought to reproduce using an in
vitro priming assay.Of note, we observed a heterogeneous effect of
in vitro priming in HCV-specific CD8 T-cell populations with a
predominantly (60%) naive-like phenotype. Indeed, prolifera-
tion ofHCV-specificCD8T cells was observed in only two of five
naive-like HCV-specific CD8 T-cell populations. Thus, the pos-
sibility of a functional impairment of naive-like HCV-specific
CD8 T cells cannot be excluded in all cases. However, viral se-
quence variations in the corresponding epitopes may also alter
antigen recognition by CD8 T cells (23). Indeed, analysis of the
viral sequences corresponding to the CD8 T-cell epitopes
NS31073 and NS31406 indicated a correlation between viral se-
quences and the proliferative capacity of HCV-specific CD8 T-
cell populations with a naive-like phenotype. Due to the limited
TABLE 2 Viral sequence variations in relation to proliferative capability of naive-like HCV-specific CD8 T cellsa
Outcome of priming NS31073 sequence NS31406 sequence
CINGVCWTV KLVALGINAV
Proliferation of naive-like T cells ------V--- (pt. 6)
--T-M----- (pt. 7)
Lack of proliferation of naive-like T cells --------- (pt. 14) ---------- (pt. 14)
---------- (pt. 5)
a Autologous bulk viral sequences that correspond to the five naive-like HCV-specific CD8 T-cell responses from Fig. 4B are shown. For each epitope, the sequence in each line
represents the sequence obtained from one patient; hyphens represent sequence homology to the genotype 1a consensus sequence. Numbers in parentheses correspond to patient
(pt.) numbers from Table 1.
FIG 5 Proliferation of patient-derived enriched detectable HCV-specific CD8 T cells occurs only in response to the consensus epitope. MD-DCs from patient
6were pulsed eitherwith theNS31406 consensus sequence orwith the autologous variant andused for in vitropriming. The frequency of PBSE
low tetramerCD8
T cells in total CD8 T cells is indicated. The altered amino acid is shown in boldface.
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number of patients with which we could perform these analyses,
this correlation should be confirmed with a larger patient cohort.
Naive-like HCV-specific CD8 T-cell populations targeting con-
sensus viral sequences could not proliferate in vitro. This may
indeed suggest a functional impairment of naive-like HCV-spe-
cific CD8T cells targeting consensus sequences in some patients,
preventing their priming during acute infection. Importantly, this
is not a general CD8 T-cell defect but rather an epitope-specific
phenomenon, since patient 5 showed an effector memory pheno-
type for NS31073 but a naive-like CD8
 T-cell population for
NS31406 that could not expand in vitro, arguing against a major
role of host-specific genetic features or low viral loads. One expla-
nation for this functional impairment may be a reduced avidity of
HCV-specific CD8 T cells for their cognate antigen mediated by
a loss of high-avidity clones from the CD8T-cell repertoire. This
could lead to reduced antigen recognition (24). A low functional
avidity may also explain why in vitro priming did not result in
proliferation of the remaining naive-like HCV-specific CD8 T
cells in patients with effectormemory phenotype responses. How-
ever, further research will be required to address this important
question, since we could not analyze the functional avidity of en-
riched detectable HCV-specific CD8 T cells because of insuffi-
cient cell numbers.
In contrast, in two patients where naive-like HCV-specific
CD8 T cells were able to proliferate in vitro, variant sequences
were obtained for the corresponding CD8 T-cell epitopes (Table
2). Importantly, this is, in our opinion, not consistent with viral
escape mutations, since we did not observe effector memory
CD8 T-cell responses toward these epitopes, arguing against im-
mune-mediated selection pressure. Thus, viral sequence varia-
tions in these epitopes were likely present in the original infecting
virus. Of note, naive-like NS31406-specific CD8
 T cells from one
of these patients proliferated only in response to the genotype 1a
consensus sequence and not in response to the autologous variant
sequence (Fig. 5). Thus, functionally competent naive-like HCV-
specific CD8 T cells likely persisted in these patients due to the
absence ofmatching antigen. In conclusion, these resultsmay sug-
gest that some HCV-specific CD8 T-cell populations have never
been primed during early infection. This lack of CD8 T-cell
primingmay bemediated either extrinsically by a variant infecting
virus or intrinsically by a functional impairment of CD8 T cells.
To our knowledge, this is the first description that, in addition to
T-cell exhaustion and viral escape mutations, a lack of CD8 T-
cell priming may limit the efficacy of HCV-specific CD8 T cells.
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